NCT00683969View on ClinicalTrials.gov

A Study to Assess the Effect of CellCept (Mycophenolate Mofetil) and Reduced Corticosteroids in Controlling Symptoms of Myasthenia Gravis

PHASE3CompletedINTERVENTIONAL

Enrollment

136

Participants

Timeline

Start Date

August 31, 2004

Study Completion Date

May 31, 2007

Conditions

Myasthenia Gravis, Generalized

Interventions

DRUG

mycophenolate mofetil (CellCept)

1g bid for 36 weeks

DRUG

placebo

po bid for 36 weeks

Trial Locations (43)

185

Roma

11000

Belgrade

12000

Jerusalem

14000

Mexico City

14607

Rochester

20097

San Donato Milanese

20133

Milan

33136

Miami

40225

Düsseldorf

43210

Columbus

61068

Kharkiv

69035

Zaporizhzhya

72076

Tübingen

75390

Dallas

77555

Galveston

81675

München

93053

Regensburg

95817

Sacramento

Unknown

Sun City

Bordeaux

Nice

Hyderabad

Mumbai

New Delhi

Kazan'

Moscow

Nizhniy Novgorad

Barcelona

Madrid

Kiev

66160-7314

Kansas City

27599-7025

Chapel Hill

19013-3395

Upland

T6G 2B7

Edmonton

N6A 5A5

London

06700

Mexico City

06726

Mexico City

2300 RC

Leiden

6202 AZ

Maastricht

3015 GD

Rotterdam

L9 1AE

Liverpool

OX2 6HE

Oxford

M6 8HD

Salford

Sponsors

Collaborators (1)

Aspreva Pharmaceuticals

All Listed Sponsors

collaborator

Aspreva Pharmaceuticals

INDUSTRY

lead

Hoffmann-La Roche

INDUSTRY

NCT00683969 - A Study to Assess the Effect of CellCept (Mycophenolate Mofetil) and Reduced Corticosteroids in Controlling Symptoms of Myasthenia Gravis | Biotech Hunter | Biotech Hunter